---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045791"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:44:45.144659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sagimet Biosciences reports Q1 net loss of $18.2M; plans Phase 1 combo trial with resmetirom in 2H 2025

## Summary
- Q1 net loss $18.2M (vs $6.6M Q1 2024); R&D expense $15.3M (vs $5.3M). Cash $144.6M.
- Phase 1 PK trial of denifanstat + resmetirom expected to start 2H 2025; data readout 1H 2026.
- End-of-Phase 2 FDA interaction completed Oct 2024; Phase 3 deferred until sufficient funding secured.
- Board changes: George Kemble to non-executive Chair; Beth Seidenberg appointed Lead Independent Director; Merdad Parsey to step off June 9, 2025.
- License partner Ascletis completed enrollment of 480-patient Phase 3 acne trial in China; topline results expected Q2 2025.

## SEC filing metadata
- accession: 0001104659-25-045791
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/0001104659-25-045791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045791
- JSON: https://secwatch.observer/filing/0001104659-25-045791.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.